Ozenoxacin belongs to a novel generation of non-fluorinated quinolones
A patient-reported study of hormonal contraceptives has found a significantly varied effect on acne among commonly prescribed agents.
The safety and efficacy of topical minoxidil for the treatment of female pattern hair loss was supported by moderate to low quality evidence in a recent Cochrane systematic review.
Regeneron and Sanofi announced that the Phase 3 study, LIBERTY AD CHRONOS, met its primary and key secondary endpoints for dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Allergan announced that the Food and Drug Administration (FDA) has approved Juvederm Volbella XC for use in lip augmentation and for correction of perioral rhytids (referred to as perioral lines) in adults aged >21 years old.
Wockhardt/Morton Grove Pharmaceuticals announced the discontinuation of Lindane Lotion 1%. The Companies have decided to stop manufacturing this product as of June 2, 2016.
The FDA has accepted for review the Biologics License Application (BLA) for SB2 (Samsung Bioepis), a biosimilar candidate to Remicade (infliximab; Janssen), for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for oxymetazoline HCl cream 1% (Allergan) for the treatment of persistent facial erythema associated with rosacea in adults.
Mirvaso (brimonidine; Galderma) Topical Gel 0.33% is now available in a pump dispenser.
The Food and Drug Administration (FDA) has approved Ameluz (aminolevulinic acid HCl; Biofrontera) gel, in combination with photodynamic therapy using BF-RhodoLED lamp, for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp.
Allergan issued a voluntary recall of two lots of Tazorac (tazarotene) Gel 0.05% due to routine stability results for one lot that were slightly below regulatory specifications for Product Concentration and Content Uniformity.
Some patients use these products on suspected skin cancers because they believe it is a convenient way to remove them.
Mission Pharmacal announced that Lycelle Head Lice Removal Kit (sodium laureth sulfate, isopropanol, citronellyl acetate, hypromellose, methyl salicylate, methylparaben, citric acid) is now available without a prescription.
Eli Lilly announced that Taltz (ixekizumab) injection is now available for the treatment of moderate-to-severe plaque psoriasis through a network of specialty pharmacies.
New findings from a study published in the American Journal of Medicine may help clinicians identify high-risk drugs and high-risk patients linked to the development of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) in order to reduce its incidence.
Regeneron and Sanofi announced that the two Phase 3 studies, LIBERTY AD SOLO 1 and SOLO 2, evaluating dupilumab for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints.
Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes.
The Food and Drug Administration (FDA) has approved Inflectra (infliximab-dyyb; Celltrion) for injection, a biosimilar to Remicade (infliximab; Janssen).
Patients with Staphylococcus aureus skin and soft tissue infections took an average of 57% of their antibiotic doses after being discharged from the hospital, a new study published in Antimicrobial Agents and Chemotherapy reported.
Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Tec Labs announced the launch of Tecnu Bites & Stings Medicated Itch and Pain Relief Wipes for treating insect bites and bee stings.
Anacor Pharmaceuticals announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) of crisaborole 2% topical ointment for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.
The FDA is reporting a shortage in certain presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).
Amgen has announced that the U.S. Food and Drug Administration (FDA) has accepted for review their supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept).
At the American Academy of Dermatology's annual meeting, researchers presented study findings supporting the safety and efficacy of ATX-101 in reducing the appearance of a double chin.
Novartis announced late-breaking data from the CLEAR study that demonstrated Cosentyx (secukinumab) was superior to Stelara (ustekinumab) in reaching near clear skin on the PASI 90 in significantly more moderate to severe psoriasis patients at Week 52.
Celgene announced long-term safety data for Otezla (apremilast) from ongoing clinical trials at the American Academy of Dermatology's Annual Meeting.
Lilly announced positive results from two Phase 3 studies, UNCOVER-2 and UNCOVER-3, of ixekizumab for the treatment of moderate-to-severe plaque psoriasis compared to etanercept or placebo. Study findings were recently presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.
Dermatoses in pregnancy provides a challenge to dermatologists when it comes to recommending treatments that are effective yet safe to the fetus.
Galderma announced the launch of qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement indicated for hair thinning and hair loss
Allergan announced that the Food and Drug Administration (FDA) has approved Aczone Gel 7.5%, a new topical treatment for acne vulgaris in patients aged ≥12 years.
The American Academy of Dermatology has released its new "Guidelines of care for the management of acne vulgaris" that includes acne treatment recommendations for adults and adolescents.
Celltrion announced that the Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of all indications for CT-P13, a biosimilar candidate of Remicade (infliximab; Janssen Biotech).
Dr. Reddy's announced that Promius Pharma has received approval for Sernivo (betamethasone dipropionate) Spray 0.05% for the treatment of mild to moderate plaque psoriasis in patients aged ≥18 years.
Dr. Reddy's Laboratories announced that the Food and Drug Administration (FDA) has granted tentative approval for Zenavod (doxycycline) capsules for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.
Amgen announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira (adalimumab).
Valeant, in partnership with AstraZeneca, announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for brodalumab injection for patients with moderate-to-severe plaque psoriasis.
Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
The Food and Drug Administration (FDA) informed that Granulex Aerosol Spray (trypsin, balsam peru, castor oil; Mylan) has been discontinued due to market conditions.
The Food and Drug Administration (FDA) is alerting healthcare professionals about possible eye and skin injuries from exposure to laser-containing products.
The Food and Drug Administration (FDA) has proposed steps to prevent the use of sunlamp products by minors and to reduce the risk of these devices for adults.
Bayer HealthCare announced the launch of Finacea Foam (azelaic acid) 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Leo Pharma announced that Enstilar (calcipotriene and betamethasone dipropionate) foam has been approved for the topical treatment of plaque psoriasis in adults aged ≥18 years.
The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate; Pfizer) for the treatment of adults with moderate to severe chronic plaque psoriasis.
Celgene announced that new findings from its ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis were presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress.
The Food and Drug Administration has granted avelumab (Pfizer/Merck) Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.
Skin rashes accompanied by a fever could be indicative of serious or life-threatening illness in adults and warrant immediate medical attention, according to a lecture to be presented at the American Osteopathic Association's Annual Osteopathic Medical Conference and Exposition (OMED).
Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Psoriasis patients, regardless of disease severity, may be at an increased risk of depression, according to a study recently published in JAMA Dermatology.
The FDA has granted Orphan Drug designation to the investigational cancer immunotherapy avelumab (Pfizer/Merck) for the treatment of Merkel cell carcinoma (MCC).
The active ingredient in household vinegar was effective in preventing infections and killing bacteria present in burn wounds, a new study has found.
Trevi Therapeutics announced statistically significant results from its Phase 2/3 trial of Nalbuphine ER for the treatment of moderate to severe uremic pruritus.
Theradome announced that it has initiated one of the most comprehensive studies to date to evaluate its Theradome LH80 PRO Laser Helmet on men with thinning hair or who are showing signs of balding.
The Food and Drug Administration (FDA) has accepted for review the sBLA for Keytruda (pembrolizumab, Merck) for the first-line treatment of unresectable or metastatic melanoma patients.
The Food and Drug Administration (FDA) is warning about reports of severe allergic reactions and herpes zoster associated with the use of Picato (ingenol mebutate topical gel).
The American Academy of Dermatology has issued new recommendations regarding potentially unnecessary dermatologic tests and treatments as part of the Choosing Wisely campaign.
Treatment-resistant lice with one or more genetic mutations have been identified in at least 25 states, according to research presented at the 250th National Meeting & Exposition of the American Chemical Society (ACS).
Galderma announced the launch of Epiduo Forte (adapalene and benzoyl peroxide) Gel for the once-daily, topical treatment of acne vulgaris.
The safety and efficacy of biologics in the treatment of pediatric psoriasis were demonstrated in several case studies published in the Journal of Drugs in Dermatology.
Psoriasis patients who experience physical trauma have an increased risk of developing psoriatic arthritis, according to a study presented at the European League Against Rheumatism Annual Conference (EULAR 2015) in Rome.
Patients taking biologic medications are more satisfied with their treatment and prefer longer dosing intervals compared to those taking other types of medicines for moderate to severe plaque psoriasis, reports a study in Patient Preference and Adherence.
Galderma announced the launch of two new additions to the Benzac Acne Solutions product line: Benzac Skin Refining Mask and Benzac Acne Eliminating Cleanser.
Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea.
The Food and Drug Administration (FDA) is warning that black henna tattoos may cause harmful skin reactions in some people.
A drug used to treat rheumatoid arthritis (RA) was effective in patients with moderate to severe eczema, according to a study conducted by researchers from Yale School of Medicine.
Galderma announced that the Food and Drug Administration (FDA) has approved Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% for the once-daily topical treatment of acne vulgaris.
At the recent 4th World Psoriasis & Psoriatic Arthritis Conference, the International Federation of Psoriasis Associations (IFPA) released the results of a global survey on significant unmet needs on the impact of psoriasis.
In a systematic review, acupuncture was found to improve outcome measures in the treatment of dermatitis, cholasma, pruritus, urticaria, hyperhidrosis, and facial elasticity.
Patients who had suffered severe burns were found to have a huge increase in Enterobacteriaceae and a decrease in beneficial bacteria, according to a study published in PLOS ONE.
Janssen Research & Development announced results from the Phase 2b X-PLORE trial with guselkumab in patients with moderate to severe plaque psoriasis.
Cosmederm Bioscience announced the expansion of its itch-relief product line featuring two new steroid-free, anti-itch products.
The Food and Drug Administration (FDA) has issued a warning that the use of Daytrana patch (methylphenidate transdermal system; Noven) may result in permanent loss of skin color.
Patients taking medications for erectile dysfunction may have an increased risk of melanoma, but these drugs are not a cause of melanoma, researchers concluded.
The Food and Drug Administration (FDA) has determined that the Boxed Warning for Potiga (ezogabine; GlaxoSmithKline) is adequate to manage the potential risks of vision loss due to pigment changes in the retina and skin discoloration.
Novartis announced results from two clinical trials on the efficacy of Costentyx (secukinumab) for the treatment of plaque psoriasis of the palms, soles, and nails in adult patients.
The Food and Drug Administration (FDA) has issued an alert regarding certain injection sites on the face where unintentional injection of soft tissue fillers into blood vessels in the face can result in rare but serious side effects.
Researchers at the NYU Langone Medical Center have reported that up to six percent of adults in New York who get tattoos have experienced some form of tattoo-related rash, severe itching, or swelling that lasted from four months up to years for some.
AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for Humira (adalimumab) as an investigational treatment for moderate-to-severe hidradenitis suppurativa (HS; Hurley Stage II and III disease).
A study presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting found that an over-the-counter form of vitamin B3 significantly reduced rates of new non-melanoma skin cancers in high-risk patients, which along with sun protection could help to decrease the health and economic burden of skin cancer.
A study published in Clinical, Cosmetic, and Investigational Dermatology showed that TriCalm hydrogel is significantly superior to diphenhydramine 2 percent and hydrocortisone 1 percent in its antipruritic effect.
The Food and Drug Administration (FDA) has accepted for filing and has granted Priority Review to the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma.
A high-dose treatment of sodium nitrite and citric acid creams applied twice daily was more effective than placebo for treating anogenital warts, according to a new study in JAMA Dermatology.
Aidance Scientific announced the launch of Terrasil Shingles Skincare Ointment, a new over-the-counter treatment to soothe highly sensitive skin in patients of all ages.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to SRX-1177 (SolaranRx) for the treatment of stage IIB to IV malignant melanoma.
The FDA is alerting healthcare providers and the public that counterfeit Botox (onabotulinumtoxin A; Allergan) has been found in the United States and may have been distributed to doctors' offices and clinics.
The FDA has granted Orphan Drug designation to Samcyprone (diphenylcylcopropenone, DPCP; RXi Pharmaceuticals) for the treatment of malignant melanoma Stage IIb to IV.
The Food and Drug Administration (FDA) is recommending that manufacturers stop using the labels "latex-free" or "does not contain latex" due to the scientific inaccuracy of these claims.
Merck announced results from the Phase 3 KEYNOTE-006 study investigating Keytruda (pembrolizumab) vs. ipilimumab in the first-line treatment of patients with advanced melanoma.
Pfizer announced results from two Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program for tofacitinib citrate in adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Celgene announced results from the ESTEEM Phase 3 clinical program for Otezla (apremilast) in patients with moderate to severe plaque psoriasis.
Over 25% of patients with acne did not obtain medications prescribed by their dermatologists, according to a survey by Wake Forest Baptist Medical Center researchers.
Galderma announced positive Phase 3 results for adapalene 0.3%/benzoyl peroxide 2.5% (0.3% A/BPO) topical gel.
Two common antibiotics have been shown to be equally effective in treating uncomplicated community-acquired skin infections like methicillin-resistant Staphylococcus aureus (MRSA), according to a new study in the New England Journal of Medicine.
An antihypertensive was found to reduce side effects from corticosteroid-based creams used for certain skin diseases, reports a study published in the Journal of Investigative Dermatology.
A new "smart bandage" has been developed that can detect early tissue damage from pressure ulcers before they are visible to the human eye.
Patients with moderate-to-severe psoriasis showed significant recovery after a single dose of an experimental human antibody treatment that targets interleukin-23, a study showed.
The Food and Drug Administration (FDA) has approved the first biosimilar product, Zarxio (filgrastim-sndz; Sandoz).
The Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab; Bristol-Myers Squibb) for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection.